Changes in the neutrophil count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the platelet count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the white blood cell count. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Changes in the hemoglobin. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

General clinical data of 88 patients with NPC. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

CONSORT participant flow diagram. by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

S4 File - by Lu Yang (30847)

“…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”

Correlations between perceptual bias scores, age, and autism-associated features: Simple linear regression showing a significant correlation between elevated proprioceptive bias an... by Daniel E. Lidstone (21567523)

Subjects:

Livestock–Crop–Mushroom (LCM) Circular System: An Eco-Friendly Approach for Enhancing Plant Performance and Mitigating Microbiological Risks by Dong Liu (115204)

“…The two biofertilizers were tested for their impacts on plant growth and potential microbial risks. The results show significant growth of oats stimulated by biofertiliser use. …”

Flowchart of the screening process. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Characteristics of included reviews. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the PRISMA assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the ROBIS assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Uvrag in Tregs is dispensable for establishment of immune tolerance and eTreg accumulation. by Erienne G. Norton (9612079)

Vps34 orchestrates Treg function in vivo. by Erienne G. Norton (9612079)

Atg14 deficiency in Tregs induces a type-I-dominant lymphoproliferative disease and cell-intrinsic reductions in eTregs. by Erienne G. Norton (9612079)

Vps34 supports Treg maintenance in lymphoid and non-lymphoid tissues. by Erienne G. Norton (9612079)

“…Two-tailed Student <i>t</i> test (<b>A</b>–<b>D</b>, <b>F</b>–<b>I</b>) or Benjamini–Hochberg test (<b>E</b>); NS, not significant. Data are compiled from 15 (<b>A</b>, <b>F</b>), 12 (<b>B</b>), 5 (<b>C</b>, <b>G</b>, <b>I</b>), 6 (<b>D</b>, lung and liver; <b>H</b>), or 2 (<b>D</b>, colon LP) independent experiments. …”

Atg14 does not contribute to terminal eTreg generation during perinatal life. by Erienne G. Norton (9612079)